Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States

被引：0
|
作者：
Desai, Rishi J. [1 ]
Solomon, Daniel H. [2 ]
Liu, Jun [3 ]
Kim, Seoyoung C. [4 ]
机构：
[1] Brigham & Womens Hosp, PharmacoEpidemiol & PharmacoEcon, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Rheumatol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2725
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Syngle, Ashit
    Kaur, Sudeep
    Verma, Inderjeet
    Syngle, Tanya
    Syngle, Vijaita
    CLINICAL RHEUMATOLOGY, 2017, 36 (08) : 1715 - 1720
  • [42] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [43] Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management
    Singh, Sukhbir
    Tiwary, Neha
    Sharma, Neelam
    Behl, Tapan
    Antil, Anita
    Anwer, Md. Khalid
    Ramniwas, Seema
    Sachdeva, Monika
    Elossaily, Gehan M.
    Gulati, Monica
    Ohja, Shreesh
    PHARMACEUTICALS, 2024, 17 (02)
  • [44] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [45] Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review
    Giollo, Alessandro
    Bissell, Lesley-Anne
    Buch, Maya H.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 697 - 708
  • [46] Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients
    Liu, Yi-Han
    Lin, Tzu-Chieh
    Yang, Yea-Huei Kao
    Chang, Hui-Jen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 73 - 73
  • [47] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Ashit Syngle
    Sudeep Kaur
    Inderjeet Verma
    Tanya Syngle
    Vijaita Syngle
    Clinical Rheumatology, 2017, 36 : 1715 - 1720
  • [48] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott, I. C.
    Kingsley, G. H.
    Scott, D. L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
  • [49] DISEASE MODIFYING ANTI-RHEUMATIC DRUG ADHERENCE IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
    Ayano, Nakayama
    Bruce, Shadbolt
    Allison, Tong
    Kathleen, Tymms
    Chandima, Perera
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 17 - 17
  • [50] The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database
    Edwards, CJ
    Arden, NK
    Fisher, D
    Saperia, JC
    Reading, I
    Van Staa, TP
    Cooper, C
    RHEUMATOLOGY, 2005, 44 (11) : 1394 - 1398
12345